Partial protection against experimental vaginal candidiasis after mucosal vaccination with heat-killed Candida albicans and the mucosal adjuvant LT(R192G)

References

• Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis CIM Infect Dis 1992; 14 Suppl 1: S148–5153.
   Google Scholar
• Fidel PL Jr and Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis CIM Microbiol Rev 1996; 9: 335–348.
   PubMedGoogle Scholar
• Brammer KW and Feczko JM. Single-dose oral fluconazole in the treatment of vaginal candidosis Ann N Y Acad Sci 1988; 544: 561–563.
   Google Scholar
• Denning DW. Can we prevent azole resistance in fungi? Lancet 1995; 346: 454–455.
   PubMed Web of Science ®Google Scholar
• Horowitz BJ. Mycotic vulvovaginitis: a broad overview. Am J Obstet Gyneco11991; 165: 1188–1192.
   PubMed Web of Science ®Google Scholar
• Fidel PL Jr, Cutright JL, Sobel JD. Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections Infect Immun 1995; 63: 4191–4194.
   Google Scholar
• Fidel PL Jr, Lynch ME, Conaway DH, Tait L, Sobel JD. Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun 1995; 63: 547–553.
   Google Scholar
• Fidel PL Jr, Luo W, Steele C, et aL Analysis of vaginal cell populations during experimental vaginal candidiasis Infect Immun 1999; 67: 3135–3140.
   Google Scholar
• Cassone A, Boccanera M, Adriani D, Santoni G, De Bemardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995; 63: 2619–2624.
   Google Scholar
• De Bemardis F, Santoni G, Boccanera M, et al. Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun 2000; 68: 3297–3304.
   PubMed Web of Science ®Google Scholar
• Fidel PL Jr, Ginsburg KA, Cutright JL, etal. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Thl-type responses following intravaginal challenge with Candida antigen. J Infect Dis 1997; 176:728–739.
   PubMedGoogle Scholar
• Levy DA, Bohbot JM, Catalan F, et al. Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis Vaccine 1989; 7: 337–340.
   Google Scholar
• Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998; 66: 5771–5776.
   Google Scholar
• Han Y, Riesselman MH, Cutler JE. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect Immun 2000; 68: 1649–1654.
   Google Scholar
• Mulero-Marchese RD, Blank KJ, Sieck TG. Genetic basis for protection against experimental vaginal candidiasis by periph-eral immunization. J Infect Dis 1998; 178: 227–234.
   Google Scholar
• Fidel PL Jr, Sobel JD. Protective immunity in experimental Candida vaginitis Res Immunol 1998; 149: 361–373; discussion 510–512.
   Google Scholar
• Fidel PL Jr, Lynch ME, Sobel JD. Candida-specific Thl-type responsiveness in mice with experimental vaginal candidiasis Infect Immun 1993; 61: 4202–4207.
   Google Scholar
• Fidel PL Jr, Lynch ME, Sobel JD. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis Infect Immun 1993; 61: 1990–1995.
   Google Scholar
• de Bemardis F, Boccanera M, Adriani D, et aL Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats Infect Immun 1997; 65: 3399–3405.
   Google Scholar
• Morris CB, Cheng E, Thanawastien A, Cardenas-Freytag L, Clements JD. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine 2000.18: 1944–1951.
   Google Scholar
• Guillobel HC, Carinhanha JI, Cardenas L, et aL Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain. Infect Immun 2000; 68: 4349–4353.
   PubMed Web of Science ®Google Scholar
• Cirdenas-Freytag L, Cheng E, Mayeux P, Domer JE, Clements JD. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis Infect Immun 1999; 67: 826–833.
   Google Scholar
• Chong C, Frieberg M, Clements JD. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine 1998; 16: 732–740.
   Google Scholar
• O'Neal CM, Clements JD, Estes MK, Conner ME Rotavirus 2/ 6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol 1998; 72:3390–3393.
   PubMed Web of Science ®Google Scholar
• Dickinson BL, Clements JD. Use of Escherichia coli Heat-labile Enterotoxin as an Oral Adjuvant. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. San Diego: Academic Press, 1996: 73–87.
   Google Scholar
• Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL J Immunol 2000; 165: 6454–6462.
   Google Scholar
• Oplinger ML, et al. Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant, LT(R192G). In: 37th Interscience Conference on Antimicrobial Agents and Che-motherapy, 1997.
   Google Scholar